Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that eight abstracts have been accepted for presentation at the 2026 ASCO ...
Enrique Velazquez Villarreal, MD, PhD, MPH, MS, reveals how AI is being used to identify early-onset CRC and enhance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback